AnaptysBio is a clinical stage biotechnology company developing antibody product candidates. Etokimab, Co.'s anti-IL-33 antibody drug candidate, inhibits the activity of the interleukin-33 cytokine that is applicable to the treatment of atopic inflammatory disorders, such as moderate-to-severe atopic dermatitis, eosinophilic asthma, chronic rhinosinusitis with nasal polyps, and potentially other allergic conditions. ANB019 inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases including generalized pustular psoriasis and palmoplantar pustulosis. Co.'s wholly-owned pipeline includes anti-inflammatory checkpoint receptor modulator antibodies. We show 15 historical shares outstanding datapoints in our ANAB shares outstanding history coverage, used to compute ANAB market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ANAB market cap history over the course of time is important for investors
interested in comparing ANAB's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ANAB versus a peer is one thing; comparing
ANAB market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ANAB can fluctuate over the course of history.
With this page we aim to empower investors researching ANAB by allowing them to research the ANAB market cap history. |
Video: The Importance of Market Cap
